Immutep (ASX: IMM) (NASDAQ : IMMP) CEO & Executive Director Marc Voigt discusses the TACTI-004 trial update and outlines the company’s next steps, including a detailed data review and strategic planning. He also highlights ongoing progress across the pipeline, with multiple programs advancing and further clinical milestones expected.
